https://www.selleckchem.com/pr....oducts/Cryptotanshin
If screening reveals potential frailty, a CGA is performed. All patients are invited to participate in the TENT study. Clinical data and blood samples for biomarker studies are collected at baseline. During follow-up, information about treatment complications, hospitalisations, functional decline, quality of life and mortality is collected. The primary outcome is the composite endpoint of functional decline or mortality at 1 year. Implementation of a routine clinical care pathway for older patients in need of intensive treatmen
Like
Comment
Share